Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Many patients with HR+, HER2− early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few ye...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Johnston, Stephen R. D., Harbeck, Nadia, Hegg, Roberto, Toi, Masakazu, Martin, Miguel, Shao, Zhi Min, Zhang, Qing Yuan, Martinez Rodriguez, Jorge Luis, Campone, Mario, Hamilton, Erika, Sohn, Joohyuk, Guarneri, Valentina, Okada, Morihito, Boyle, Frances, Neven, Patrick, Cortés, Javier, Huober, Jens, Wardley, Andrew, Tolaney, Sara M., Cicin, Irfan, Smith, Ian C., Frenzel, Martin, Headley, Desirée, Wei, Ran, San Antonio, Belen, Hulstijn, Maarten, Cox, Joanne, O’Shaughnessy, Joyce, Rastogi, Priya
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2020
Onderwerpen:
RAPID COMMUNICATIONS
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768339/
https://ncbi.nlm.nih.gov/pubmed/32954927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02514
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items